MergerLinks Header Logo

Announced

Completed

Maverick Capital, M28 Capital, and Population Health Partners led a $100m Series F Round in Fractyl.

Synopsis

Maverick Capital, M28 Capital, and Population Health Partners led a $100m Series F Round in Fractyl, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic. "We’re immensely proud of the leadership role Fractyl has established in creating innovative treatments to address the root cause of metabolic disease, with an initial focus on type 2 diabetes. The closing of this Series F financing, the significant experience of our new board members and our company’s renaming as Fractyl Health reflect the momentum we have built and the vast potential that lies ahead for our approach," Harith Rajagopalan, Fractyl CEO.

Show Details & Financials

Market Context

Sort

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US